Factors predicting subcutaneous implanted central venous port function: The relationship between catheter tip location and port failure in patients with gynecologic malignancies

被引:28
作者
Cohn, DE [1 ]
Mutch, DG [1 ]
Rader, JS [1 ]
Farrell, M [1 ]
Awantang, R [1 ]
Herzog, TJ [1 ]
机构
[1] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA
关键词
central venous access; implanted port; catheter tip;
D O I
10.1006/gyno.2001.6433
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. We set out to determine the factors that predict subcutaneous implanted central venous port function. Specifically, we sought to determine whether the location of the catheter tip is correlated with port failure. Methods. A review of all gynecologic oncology patients who underwent initial port placement between 1993 and 1998 was undertaken. The initial chest radiograph following port placement was reviewed, and the venous location of the catheter tip was recorded. Patients were followed until port removal, death, or the last documentation of port function. Results. Two hundred thirty-six patients underwent port placement during the study period. The majority of patients (97%) had their port placed for intravenous chemotherapy. The median time of port duration in patients with a functional port was 21.6 months. Forty of the 236 ports (17%) were removed because of device malfunction. Catheter tips were located in the central venous system in 164 (69%) cases and outside of the central venous system in 72 (31%) cases. Removal secondary to malfunction was significantly higher when the catheter tip was located outside of the central venous system (30/72 (42%) versus 10/164 (6%), P = 0.001). By life-table analysis, ports remove for malfunction with their tips located centrally had a significantly longer median duration of functional use than those whose tips were located peripherally (78 versus 44 months, P 0.0001). Conclusions. The rate of port removal secondary to malfunction is significantly less if the catheter tip is located in the central venous system. Confirmation of the location of the catheter tip is imperative for the long-term function of a subcutaneous implanted central venous port. (C) 2001 Academic Press.
引用
收藏
页码:533 / 536
页数:4
相关论文
共 17 条
[1]   VERY LOW-DOSES OF WARFARIN CAN PREVENT THROMBOSIS IN CENTRAL VENOUS CATHETERS - A RANDOMIZED PROSPECTIVE TRIAL [J].
BERN, MM ;
LOKICH, JJ ;
WALLACH, SR ;
BOTHE, A ;
BENOTTI, PN ;
ARKIN, CF ;
GRECO, FA ;
HUBERMAN, M ;
MOORE, C .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :423-428
[2]   Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life [J].
Bow, EJ ;
Kilpatrick, MG ;
Clinch, JJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1267-1273
[3]  
BROTHERS TE, 1988, SURG GYNECOL OBSTET, V166, P295
[4]   COMPLICATIONS OF INDWELLING VENOUS ACCESS DEVICES IN CANCER-PATIENTS [J].
EASTRIDGE, BJ ;
LEFOR, AT .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :233-238
[5]   TOTALLY IMPLANTED SYSTEM FOR INTRAVENOUS CHEMOTHERAPY IN PATIENTS WITH CANCER [J].
GYVES, J ;
ENSMINGER, W ;
NIEDERHUBER, J ;
LIEPMAN, M ;
COZZI, E ;
DOAN, K ;
DAKHIL, S ;
WHEELER, R .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) :841-845
[6]  
Kearns Patrick J., 1996, Journal of Parenteral and Enteral Nutrition, V20, P20, DOI 10.1177/014860719602000120
[7]  
KOONINGS PP, 1994, J AM COLL SURGEONS, V178, P164
[8]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[9]   EXPERIENCE WITH THE INTRAVENOUS TOTALLY IMPLANTED PORT IN PATIENTS WITH GYNECOLOGIC MALIGNANCIES [J].
NELSON, BE ;
MAYER, AR ;
TSENG, PC ;
SCHWARTZ, PE .
GYNECOLOGIC ONCOLOGY, 1994, 53 (01) :98-102
[10]  
NIEDERHUBER JE, 1982, SURGERY, V92, P706